Inherited lipoic acid biosynthesis defect
MONDO:0018424An inherited metabolic disease that is has its basis in the disruption of lipoate biosynthetic process.
Also known as: inborn error of lipoate biosynthetic process, inborn lipoate biosynthetic process disorder, lipoate biosynthesis defect, rare inborn error of lipoate biosynthetic process, lipoic acid biosynthesis defect, lipoic acid biosynthesis defects
15 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase 2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New study reveals how kids with language delays learn vocabulary
Knowledge-focused CompletedThis study looked at how the way words sound (phonotactic probability) and how they are spelled (orthography) affect vocabulary learning in 23 children with low oral language skills (DLD). All children took part in the same 12-week program, which used real words to improve vocabu…
Sponsor: Arizona State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC